October was an insight-rich month in Huntington’s disease research: additional clarity around uniQure’s AMT-130, mapping how and where HD changes the brain, early mechanistic studies targeting DNA ...
Why do some brain cells die first in HD? New study shows changes in gene activity begin at birth in mice, especially in striatum & cortex—mapped with spatial & single-cell tools. A new study in mouse ...
Not every news source put out a headline that exaggerated the results. Some of the more level-headed articles underscored ...
We’re back for Day 2 of Huntington’s Disease (HD) Clinical Research Congress in Nashville, Tennessee! Daniel Claassen from HSG and Cristina Sampaio from CHDI kick off the meeting with an overview of ...
We’re proud to announce Gravity Guignard as a 2025 HDBuzz Prize winner! A new study points to one of the reasons why past HD trials might have failed. The good news? This shows the path to safer drugs ...
UniQure has announced positive top-line results from its Phase I/II trial of AMT-130, a one-time gene therapy being tested in people with Huntington’s disease (HD). Topline data is a summary of the ...
Every cell in our body is constantly fixing DNA damage that happens throughout our lifetime. Like a city sending out crews to mend roads and power lines, our cells rely on specialized proteins to keep ...
Pridopidine has been under investigation as a treatment for Huntington’s disease (HD) since the early 2000s. The most recent Phase 3 trial testing to see if pridopidine might improve signs and ...
Two research teams have uncovered how a small change in FAN1, a DNA repair protein, can speed up Huntington’s disease (HD). In back-to-back papers in Nature Communications, they show how a single ...
Huntington’s disease (HD) is typically viewed as a brain disorder, but new research highlights its lesser-known effects on the body, especially on muscles, fat, and nutrition, even in the early stages ...
Full Steam Ahead: uniQure’s On Track With Hope for Accelerated Approval of Huntington’s Disease Drug
We’ve been following the development of uniQure’s HTT-lowering drug, AMT-130, from its genesis in the lab, to animal studies just a few years ago, and now through to their ongoing Phase 1/2 clinical ...
Seeking dental care and adhering to recommended routines is tough for lots of folks, even under the best of circumstances. Throw Huntington’s disease (HD) into the mix, and oral health can get even ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback